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Mycoplasma amphoriforme was first isolated in 1999 from an immunocompromised patient with chronic bronchitis in the UK (1) . Subsequently, the species was isolated from patients with respiratory tract infections in the UK, Denmark, France, and Tunisia but had not been isolated in Japan (1) (2) (3) . In this study, we detected M. amphoriforme while investigating Mycoplasma pneumoniae and reported details regarding both the bacterium and patient.
From October 2013 to January 2016, we investigated 406 patients with suspected M. pneumoniae infections, of which 403 patients were aged 15 years or younger and 3 patients were aged 16 years or older, to identify the prevalence of M. pneumoniae infections. Throat swabs were collected from 3 hospitals and 6 clinics in Osaka, kept in BD Universal Viral Transport System (Nippon Becton Dickinson Inc., Tokyo, Japan), and cryopreserved until further examination. DNA was extracted from the specimens using the QIAamp DNA Mini Kit (QIAGEN, Tokyo, Japan) and M. pneumoniae genes were detected by real-time quantitative PCR (qPCR) (4) . Moreover, the specimens were inoculated in both diphasic mycoplasma medium and PPLO broth (Nippon Becton Dickinson Inc.) that was supplemented with horse serum (Thermo Fisher Scientific K. K., Kanagawa, Japan) and yeast extract, which we prepared using dry yeast (Nippon Beet Sugar Manufacturing Co., Ltd., Tokyo, Japan) (5). PCR was performed to identify the isolated bacteria (6) . Of the 406 specimens, 194 specimens (47.8z) became positive for M. pneumoniae using either qPCR or culturing. In detail, 186 specimens were positive for M. pneumoniae using qPCR and 188 M. pneumoniae isolates were detected by culturing. Moreover, 1 isolate, designated as M151, was obtained by culturing but not identified as M. pneumoniae by the specific PCR. The M151 isolate grew in PPLO broth, but did not grow in the diphasic mycoplasma medium and PPLO agar. Furthermore, the M151 isolate was able to pass through a membrane filter of 0.45-mm pore size similar to M. pneumoniae and catabolized glucose, but could not hydrolyze arginine in the PPLO broth. Therefore, 16S rRNA gene sequence analysis was performed to identify the M151 isolate. The 16S rRNA gene sequence of M151 showed 99.9z identity (1408/1409, partial 16S rRNA gene sequence) to that of the previously reported M. amphoriforme A39 (GenBank accession number NR_117836). Furthermore, M151 was qPCR positive for M. amphoriforme (7); thus, the isolate M151 was identified as M. amphoriforme. The partial 16S rRNA gene sequence of M. amphoriforme M151 has been deposited in DDBJ/ ENA/GenBank databases under the accession number LC131338.
The minimum inhibitory concentrations (MIC) of erythromycin (EM), clarithromycin (CAM), azithromycin (AZM), clindamycin (CLDM), tetracycline (TC), minocycline (MINO), ciprofloxacin (CPFX), levofloxacin (LVFX), moxifloxacin (MFLX), and gatifloxacin (GFLX) for M. amphoriforme M151 were determined by the broth microdilution method using the Dry Plate Eiken (Eiken Chemical Co., Ltd., Tokyo, Japan). The MIC values of the drugs for M. amphoriforme M151 were comparable to those for M. pneumoniae M129, which was the M. pneumoniae susceptible reference strain ( Table 1 ). The isolate M151 was susceptible to antibiotics that are usually used for mycoplasmal infections.
The details of the patient infected with M. amphoriforme are explained here. In August 2015, a 4-year-old girl, patient No. 7 (Table 2) , visited the Asai Children's Clinic for evaluation of a cough, which had persisted for 3 months without fever, nasal discharge, or other systemic findings. Her white blood cell count was 9.0 × 10 9 /L with 53z neutrophils, and her C-reactive protein level was 0 mg/L. She had no abnormal findings in the biochemical tests and had no underlying disease. Her antibody titer for M. pneumoniae, assessed using the particle agglutination test (SERODIA MYCO II, Fujirebio Inc., Tokyo, Japan) was 1:320, indicating that she was antibody positive for a M. pneumoniae infection because results of 1:320 titer or higher with single serum were considered positive. However, she was negative for M. pneumoniae by qPCR, which was also not detected by the culture test. A fluoroquinolone antibiotic, tosufloxacin, was administered as an outpatient treatment for 8 days; the symptoms of her cough disappeared and she experienced an uneventful recovery. Because culturing is difficult for fastidious organisms like M. amphoriforme (2), we performed genetic screening for all 406 specimens to detect whether a trace of M. amphoriforme was present. We demonstrated that 9 specimens (2.2z) were M. amphoriforme DNA positive (Table 2 ) using qPCR for M. amphoriforme (7). However, M. amphoriforme was not detected by culturing these specimens, except in the specimen from which M. amphoriforme M151 was isolated. Additionally, 4 of these specimens were found to be M. pneumoniae positive not only by qPCR for M. pneumoniae, but also by culturing (Table 2 ). Therefore, these 4 patients were suspected to have coinfection with M. amphoriforme and M. pneumoniae. Patients coinfected with M. amphoriforme and M. pneumoniae generally exhibited symptoms of high fever, in contrast to 4 of the 5 patients infected with M. amphoriforme, who exhibited no or mild fever. Apart from the M. amphoriforme culture-positive patient, the other 8 patients also did not have an underlying disease. Coinfected patient No. 5 was the older brother of patient No. 7, who was M. amphoriforme culture positive. Because the antibody titer for M. pneumoniae was high in patient No. 7, we considered that there might have been a coinfection with M. amphoriforme and M. pneumoniae during the 3-month period of protracted bronchitis. The fact that 5 coinfections were identified in this study demonstrated that there is some type of association between these 2 bacteria. The possibility that M. amphoriforme exacerbates a M. pneumoniae infection is postulated.
Because M. amphoriforme is fastidious and catabolizes glucose similar to M. pneumoniae, detecting this species from a culture is very difficult. qPCR is an effective tool for detecting M. amphoriforme and was used to identify M. amphoriforme and M. pneumoniae coinfection in this investigation. Viral coinfections have also been reported (7); therefore, further studies on the detection of M. amphoriforme in patients with various types of respiratory infections are required.
